Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Mol Genet Metab. 2021 Apr 8;133(2):148–156. doi: 10.1016/j.ymgme.2021.04.001

Figure 4. Repeat biomarker evaluation.

Figure 4.

Repeat biomarker evaluation was performed on 13 participants approximately one year after initial evaluation. The year 1 and year 2 values for each biomarker for each individual are shown. The red line indicates the cutoff for normal vs. abnormal values provided by manufacturer or laboratory for liver stiffness obtained by SWE, ActiTest™ and FibroTest™. For FIB-4 and APRI, the red line indicates cutoffs determined in individuals with hepatitis C [36, 37].